Bibliography
- Goldberg JF, Brooks JO III, Kurita K, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry 2009;70(2):155-62
- Stroup TS, Lieberman JA, McEvoy JP, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009;107(1):1-12
- Wisniewski SR, Rush AJ, Nierenberg AA, et al. Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report. Am J Psychiatry 2009;166(5):599-607
- Pharmaprojects Database, © Informa UK Ltd, 2009
- Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41
- Wallingford NM, Sinnayah P, Bymaster FP, et al. Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. Neuropsychopharmacology 2008;33(12):2922-33
- Musselman DL, Betan E, Larsen H, et al. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003;54(3):317-29
- Rush AJ, Giles DE, Schlesser MA, et al. The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatry 1996;57(10):470-84
- Knable MB, Torrey EF, Webster MJ, et al. Multivariate analysis of prefrontal cortical data from the Stanley Foundation Neuropathology Consortium. Brain Res Bull 2001;55(5):651-9
- Iijima M, Chaki S. An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(3):622-7
- Griebel G, Simiand J, Serradeil-Le GC, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA 2002;99(9):6370-5
- Souppart C, Gardin A, Greig G, et al. Pharmacokinetics of licarbazepine in healthy volunteers: single and multiple oral doses and effect of food.J Clin Pharmacol 2008;48(5):563-9
- Ambrosio AF, Soares-Da-Silva P, Carvalho CM, et al. Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002;27(1-2):121-30
- Lippa A, Czobor P, Stark J, et al. Selective anxiolysis produced by ocinaplon, a GABA(A) receptor modulator. Proc Natl Acad Sci USA 2005;102(20):7380-5
- McIntyre RS, Panjwani ZD, Nguyen HT, et al. The hepatic safety profile of duloxetine: a review. Expert Opin Drug Metab Toxicol 2008;4(3):281-5
- Cohen C, Bergis OE, Galli F, et al. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003;306(1):407-20
- Lamota L, Bermudez-Silva FJ, Marco EM, et al. Effects of adolescent nicotine and SR 147778 (Surinabant) administration on food intake, somatic growth and metabolic parameters in rats. Neuropharmacology 2008;54(1):194-205
- Available from: www.clinicaltrials.gov